Progressive abrogation of TGF‐β‐1 and EGF growth control is associated with tumour progression in ras‐transfected human keratinocytes

International Journal of Cancer

Volumn 52, Issue 3, 1992, Pages 461-470

  Game, S M ^a   Huelsen, A ^b   Patel, V ^a   Donnelly, M ^a   Yeudall, W A ^a   Stone, A ^a   Fusenig, N E ^b   Prime, S S ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KERATINOCYTE; MOUSE; NONHUMAN; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR GROWTH;

CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; GENES, RAS; HUMAN; KERATINOCYTES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CELL SURFACE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SUPPORT, NON-U.S. GOV'T; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

EID: 0026662423     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910520322     Document Type: Article

References (28)

1. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line
2. c‐Ha‐ras oncogene expression in immortalised human keratinocytes (haCaT) alters growth potential in vivo hut lacks correlation with malignancy
3. Epidermal growth factor
4. Transformation of mouse mammary epithelial cells with the Ha‐ras but not the neu oncogene results in gene dosage‐Dependent increase in transforming growth factor‐α production
5. In vitro transformation of human skin epithelial cells, role of ras oncogene in malignant progression
6. Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF‐P receptor expression and altered responses to these growth factors
7. Characterisation of the mouse transforming growth factor‐Pi promoter and activation by the Ha‐ras oncogene
8. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers
9. Lack of correlation between sensitivity to growth inhibition and receptor number for transforming growth factor β in human squamous carcinoma cell lines
10. Inhibition of endothelial cell regeneration by type‐Beta transforming growth factor from platelets
11. Specific effects of ras oncogene expression on the growth and histogenesis of human epidermal keratinocytes
12. Introduction of a Ha‐ras oncogene into rat liver epithelial cells and parenchymal hepatocytes confers resistance to the growth inhibitory effects of TGF‐Beta
13. Regulation of transforming growth factor β 1 action by multiple transducing pathways: evidence for both G protein‐Dependent and ‐Independent signalling
14. Biological effects and binding properties of transforming growth factor on human oral squamous cell carcinoma cells
15. Production of transforming growth factor‐α in human tumour cell lines
16. Responsiveness to transforming growth factor‐Beta (tGF‐Beta) restored by genetic complementation between cells defective in TGF‐Beta receptor‐I and receptor II
17. Concomitant loss of transforming growth factor (tGF) ‐β receptor types I and II in TGF‐β‐Resistant cell mutants implicates both receptor types in signal transduction
18. The transforming growth factor‐P family
19. Transforming growth factor‐β modulates the high affinity receptors for epidermal growth factor and transforming growth factor‐α
20. Escape from transforming growth factor p control and oncogene cooperation in skin tumor development
21. Transforming growth factor β 1 suppression of c‐myc gene transcription: role in inhibition of keratinocyte proliferation
22. The behaviour of human oral squamous carcinoma in cell culture
23. Loss of growth responsiveness to epidermal growth factor and enhanced production of alpha transforming growth factor in ras‐Transformed mouse mammary epithelial cells
24. Reversible inhibition of normal human prokeratinocyte proliferation by type p transforming growth factor—growth inhibitor in serum‐Free medium
25. A point mutation in the neu oncogene mimics ligand induction of receptor aggregration
26. Early gene responses to transforming growth factor‐β in cells lacking growth‐Suppressive RB function